PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8228208-11	1993	The fall in blood pressure with lisinopril was related to baseline plasma renin activity, whereas when amlodipine was given, either alone or in combination, the fall in blood pressure was independent of baseline renin activity.	Lisinopril	32-42	renin	Homo sapiens	74-79	
8228208-14	1993	CONCLUSIONS: The results of the present study indicate that: amlodipine and lisinopril in combination have a marked additional effect on blood pressure compared with either given as a monotherapy; their potentiation of action is long-acting; Black patients tend not to respond to the monotherapy with lisinopril as well as Caucasian patients, although they respond similarly to the combination; the response to amlodipine tends to be greater the higher the initial blood pressure; and, finally, the response to lisinopril is greater the higher the plasma renin activity.	Lisinopril	76-86	renin	Homo sapiens	555-560	
1662562-0	1991	Different hemodynamic (24-h ambulatory blood pressure monitoring) and renin-inhibiting effect of a 1-week treatment with enalapril and lisinopril.	Lisinopril	135-145	renin	Homo sapiens	70-75	
1329475-7	1992	Moreover, administration of once-daily lisinopril 10 mg resulted in a decrease in plasma concentrations of angiotensin II, aldosterone, and atrial natriuretic peptide, and an increase in plasma concentrations of active renin.	Lisinopril	39-49	renin	Homo sapiens	219-224	
2550029-7	1989	We conclude (1) there is a heterogeneous response to lisinopril in patients with chronic renal disease and hypertension, (2) lisinopril monotherapy may result in effective blood pressure control without renal hemodynamic compromise, and (3) an increase in PRA following converting enzyme inhibition may identify those in whom the circulating renin angiotensin system is participating in systemic hypertension and intrarenal hemodynamic changes.	Lisinopril	125-135	renin	Homo sapiens	342-347	
33769277-6	2021	SNVs in AGT (p = 0.0141), REN (p = 0.0192), and ACE2 (p = 0.0002) were found to be associated with successful treatment on lisinopril.	Lisinopril	123-133	renin	Homo sapiens	26-29	
2540224-6	1989	Lisinopril administration resulted in a rise in plasma renin activity and a fall in plasma aldosterone concentrations which were similar in both groups and which returned over time toward the baseline.	Lisinopril	0-10	renin	Homo sapiens	55-60	
2540224-8	1989	Lisinopril alone or in combination with hydrochlorothiazide produces favorable antihypertensive effects in both younger and older predominantly black, low-renin patients with essential hypertension.	Lisinopril	0-10	renin	Homo sapiens	155-160	
10193670-0	1999	Effects on plasma angiotensin-converting enzyme activity and circulating renin of lisinopril and enalapril alone and in combination with propranolol in healthy volunteers.	Lisinopril	82-92	renin	Homo sapiens	73-78	
21219847-9	2010	12 months dual blockade of the renin-angiotensin system with candesartan and lisinopril reduced ambulatory PP levels compared with high-dose lisinopril monotherapy in hypertensive T2DM subjects.	Lisinopril	77-87	renin	Homo sapiens	31-36	
17184180-1	2007	Lisinopril is an inhibitor of the renin-angiotensin system.	Lisinopril	0-10	renin	Homo sapiens	34-39	
10371365-6	1999	Lisinopril, but not sampatrilat, increased plasma renin activity.	Lisinopril	0-10	renin	Homo sapiens	50-55	
2442549-7	1987	Lisinopril inhibits ACE activity, thereby reducing plasma angiotensin II and aldosterone and increasing plasma renin activity.	Lisinopril	0-10	renin	Homo sapiens	111-116	
2442558-7	1987	The analysis of the hormonal parameters indicate potent inhibition of the renin-angiotensin-aldosterone system for a period exceeding 24 h. In the pharmacokinetic study, 12 hospitalized patients with chronic CHF received lisinopril both orally and intravenously, with each dose followed by a 72-h arterial blood and urine sampling schedule.	Lisinopril	221-231	renin	Homo sapiens	74-79	
10193670-6	1999	Plasma renin activity increased almost ten times after ingestion of both angiotensin-converting enzyme inhibitors, but the effect lasted significantly longer after lisinopril than after enalapril.	Lisinopril	164-174	renin	Homo sapiens	7-12	
9869013-7	1998	RESULTS: Lisinopril induced a marked increase in plasma renin activity (from 1.1+/-0.2 to 6.4+/-1.3 ng/ml per h, P< 0.01) and a reduction in mean arterial pressure (from 109.6+/-3.1 to 98.7+/-2.9 mmHg, P < 0.01) without affecting the heart rate.	Lisinopril	9-19	renin	Homo sapiens	56-61	
8698434-4	1996	Lisinopril treatment increased plasma renin activity and reduced 24-hour systolic and diastolic pressures (from 159 +/- 14 to 121 +/- 8 and from 103 +/- 7 to 80 +/- 3 mm Hg, respectively) and left ventricular mass index (from 159 +/- 33 to 134 +/- 26 g/m2); moreover, in 12 of 30 patients, left ventricular mass normalization was achieved.	Lisinopril	0-10	renin	Homo sapiens	38-43	
9797801-9	1998	Lisinopril but not sampatrilat significantly increased plasma renin activity, whereas sampatrilat but not lisinopril significantly increased urinary cGMP excretion.	Lisinopril	0-10	renin	Homo sapiens	62-67	
8751015-2	1995	Compared to placebo, lisinopril significantly decreased blood pressure, increased plasma renin activity without altering heart rate or plasma norepinephrine.	Lisinopril	21-31	renin	Homo sapiens	89-94	
8136111-8	1994	A significant increase of plasma renin activity and a significant decrease of plasma aldosterone was observed in these patients after treatment with lisinopril.	Lisinopril	149-159	renin	Homo sapiens	33-38	
7789045-5	1995	The influence of the angiotensin-converting enzyme inhibitor, lisinopril, on the response of the renin-angiotensin system and serum potassium to nebulized salbutamol was investigated in a randomized, double-blind, crossover study in eight healthy volunteers using a factorial block design.	Lisinopril	62-72	renin	Homo sapiens	97-102